Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Verastem announced publication in Gynecologic Oncology of two-year follow-up data from the Phase 2 RAMP 201 study of AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer. With a median follow-up of 24.9 months, the combination showed a median duration of response of 31.1 months and median PFS of 12.9 months, consistent with the primary analysis that supported the May 2025 FDA accelerated approval for KRAS-mutated recurrent LGSOC.
Key figures
- Drug Name
- AVMAPKI FAKZYNJA CO-PACK (avutometinib; defactinib)
- Phase Of Trial
- Phase 2
- Median pfs
- 12.9 months
- Kras mt pfs
- 19.6 months
- Median followup
- 24.9 months
- Kras wt dor increase
- 9.2 to 12 months
- Ae discontinuation rate
- 12%
- Median duration of response
- 31.1 months
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.